GlassScriptPhysician profile
Brody L Henkel
NPI 1164511168
$261,687.89
in general payments reported to CMS, 2019-2025
70 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $32K · 2021: $65K · 2022: $59K · 2023: $16K · 2024: $36K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $12K · Honoraria: $6,325 · Travel and Lodging: $5,760 · Consulting Fee: $5,725 · Education: $28.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,931.25 |
| Food and Beverage | $11,777.26 |
| Honoraria | $6,325.00 |
| Travel and Lodging | $5,760.20 |
| Consulting Fee | $5,725.00 |
| Education | $28.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164,462.04 | 2019-2025 | |
| Allergan, INC. | $44,656.77 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $15,079.33 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $8,966.67 | 2022 | |
| Axsome Therapeutics, INC. | $6,554.60 | 2025 | Symbravo |
| Pfizer INC. | $5,749.95 | 2019-2025 | |
| Lundbeck LLC | $1,615.60 | 2019-2025 | Vyepti |
| Biogen, INC. | $1,309.87 | 2019-2025 | Tysabri, Vumerity |
| Ucb, INC. | $1,303.33 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Banner Life Sciences, LLC | $1,019.49 | 2021-2023 | |
| Emd Serono, INC. | $938.47 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $621.62 | 2019-2025 | Amyvid, Reyvow, Emgality |
| Genzyme Corporation | $587.33 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $529.20 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $507.82 | 2019-2024 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $473.28 | 2019-2025 | Uplizna |
| Tanabe Pharma America, INC. | $471.57 | 2019-2025 | Radicava |
| Takeda Pharmaceuticals U.S.A., INC. | $383.90 | 2020-2025 | Hyqvia, Gammagard |
| Corium, LLC | $364.46 | 2021-2025 | Azstarys, Adlarity |
| Celgene Corporation | $349.47 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $336.89 | 2019-2024 | Ultomiris, Soliris |
| Acorda Therapeutics, INC | $330.34 | 2019-2023 | Inbrija, Ampyra |
| Avanir Pharmaceuticals, INC. | $299.08 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $299.00 | 2019-2021 | |
| Tg Therapeutics, INC. | $260.34 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $236.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $232.48 | 2019-2022 | |
| Csl Behring | $232.01 | 2022-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $227.11 | 2019-2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $189.02 | 2019-2025 | Ponvory |
| Horizon Therapeutics Plc | $180.62 | 2021-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $177.17 | 2023-2025 | Nuedexta, Rexulti |
| Merz Pharmaceuticals, LLC | $175.61 | 2021-2025 | Xeomin |
| Supernus Pharmaceuticals, INC. | $168.75 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $161.08 | 2020-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $152.14 | 2019-2023 | Rytary |
| Neurocrine Biosciences, INC. | $137.11 | 2022-2023 | Ongentys, Ingrezza |
| Teva Pharmaceuticals USA, INC. | $134.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $134.35 | 2021-2022 | |
| Genentech USA, INC. | $131.87 | 2019-2024 | Enspryng |
| Merz North America, INC. | $107.49 | 2019 | |
| Argenx US, INC. | $105.11 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Azurity Pharmaceuticals, INC. | $99.11 | 2023-2025 | Horizant, Horizant |
| Tonix Medicines, INC. | $93.94 | 2024-2025 | Zembrace Symtouch |
| Sumitomo Pharma America, INC. | $87.37 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $86.08 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $65.20 | 2020-2021 | |
| Noven Therapeutics, LLC | $65.08 | 2023-2024 | Xelstrym |
| Avion Pharmaceuticals | $63.91 | 2022-2023 | Dhivy |
| Eisai INC. | $62.33 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $61.94 | 2020-2021 | |
| Kyowa Kirin, INC. | $59.60 | 2024 | Nourianz |
| Tris Pharma INC | $56.59 | 2022-2023 | Dyanavel Xr |
| Impel Pharmaceuticals LLC | $56.58 | 2025 | Trudhesa |
| Harmony Biosciences LLC | $55.27 | 2021-2022 | |
| Neos Therapeutics, LP | $53.91 | 2020-2025 | Adzenys Xr-Odt |
| Scilex Pharmaceuticals INC. | $47.15 | 2023-2024 | Ztlido |
| Catalyst Pharmaceuticals, INC. | $40.25 | 2024 | |
| Tersera Therapeutics LLC | $35.64 | 2019 | |
| Adlon Therapeutics L.P. | $34.31 | 2021 | |
| Assertio Therapeutics, INC. | $28.11 | 2019 | |
| Currax Pharmaceuticals LLC | $26.82 | 2020 | |
| Collegium Pharmaceutical, INC. | $24.74 | 2022 | |
| Bausch Health US, LLC | $23.37 | 2019 | |
| Janssen Biotech, INC. | $21.04 | 2025 | |
| Almatica Pharma LLC | $20.58 | 2021 | |
| Neuronetics, INC. | $19.86 | 2025 | Neurostar Tms Therapy System |
| Neurelis, INC. | $17.63 | 2025 | Valtoco |
| Zyla Life Sciences, INC. | $15.40 | 2020 | |
| Promius Pharma LLC | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brody Henkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.